Showing results (51-60 of 68) with videos related to
Sort By:
Pageof 7
Bioorganic & Medicinal Chemistry Letters|February 9, 2011
The design and synthesis of novel N-hydroxyformamide inhibitors of ADAM-TS4 for the treatment of osteoarthritisChris De Savi, Andrew Pape, John G Cumming, et al.Journal of Medicinal Chemistry|July 11, 2024
Discovery of a Series of Orally Bioavailable Androgen Receptor Degraders for the Treatment of Prostate CancerSharan K Bagal, Peter C Astles, Coura Diène, et al.Bioorganic & Medicinal Chemistry Letters|July 30, 2020
Identification of a novel series of azabenzimidazole-derived inhibitors of spleen tyrosine kinaseSameer P Kawatkar, Bernard Barlaam, Paul Kemmitt, et al.Journal of Medicinal Chemistry|January 15, 2019
Tricyclic Indazoles-A Novel Class of Selective Estrogen Receptor Degrader AntagonistsJames S Scott, Andrew Bailey, David Buttar, et al.Medchemcomm|October 18, 2016
Discovery of 4,6-disubstituted pyrimidines as potent inhibitors of the heat shock factor 1 (HSF1) stress pathway and CDK9Carl S Rye, Nicola E A Chessum, Scott Lamont, et al.Journal of Medicinal Chemistry|April 5, 2017
Structure-Guided Discovery of Potent and Selective Inhibitors of ERK1/2 from a Modestly Active and Promiscuous Chemical Start PointRichard A Ward, Paul Bethel, Calum Cook, et al.Journal of Medicinal Chemistry|April 8, 2015
Structure-Based Design of Potent and Selective Inhibitors of the Metabolic Kinase PFKFB3Scott Boyd, Joanna L Brookfield, Susan E Critchlow, et al.Journal of Medicinal Chemistry|November 28, 2017
Discovery and Optimization of Pyrrolopyrimidine Inhibitors of Interleukin-1 Receptor Associated Kinase 4 (IRAK4) for the Treatment of Mutant MYD88<sup>L265P</sup> Diffuse Large B-Cell LymphomaJames S Scott, Sébastien L Degorce, Rana Anjum, et al.Bioorganic & Medicinal Chemistry Letters|June 3, 2023
Optimization of a series of novel, potent and selective Macrocyclic SYK inhibitorsNeil P Grimster, Lakshmaiah Gingipalli, Amber Balazs, et al.Bioorganic & Medicinal Chemistry Letters|July 28, 2020
Optimization of a series of potent, selective and orally bioavailable SYK inhibitorsNeil P Grimster, Lakshmaiah Gingipalli, Bernard Barlaam, et al.Pageof 7